Table 2 Effect of linagliptin treatment on primary and secondary outcome parameters
Linagliptin | Placebo | p-valuea | |||||
|---|---|---|---|---|---|---|---|
Baseline | 3 months | Δ | Baseline | 3 months | Δ | ||
Global Arginine Bioavailability Ratio (GABR) | 0.9 ± 0.36 | 0.81 ± 0.29 | − 0.11 ± 0.35 | 0.93 ± 0.31 | 0.86 ± 0.35 | − 0.06 ± 0.39 | 0.608 |
Arginine to Ornithine Ratio (AOR) | 1.13 ± 0.48 | 1.02 ± 0.38 | − 0.13 ± 0.45 | 1.15 ± 0.36 | 1.10 ± 0.47 | − 0.05 ± 0.53 | 0.549 |
FMD (%) | 3.5 ± 3.1 | 3.9 ± 3.3 | 0.4 ± 4.8 | 4.0 ± 2.9 | 3.5 ± 3.3 | − 0.5 ± 3.0 | 0.486 |
NMD (%) | 14.0 ± 5.9 | 13.2 ± 6.4 | 1.1 ± 7.4 | 13.6 ± 5.2 | 12.9 ± 4.9 | − 0.7 ± 5.1 | 0.963 |
sICAM-1 (ng/ml) | 929 (692 to 992) | 922 (514 to 995) | − 15 (− 272 to 103) | 852 (547 to 1164) | 914 (597 to 1030) | − 21 (− 134 to 310) | 0.903 |
sVCAM-1 (ng/ml) | 755 ± 80 | 712 ± 189 | − 34 ± 84 | 713 ± 271 | 716 ± 264 | 5 ± 130 | 0.431 |
C-peptide (mg/dl) AUC | 370 ± 162 | 353 ± 183 | − 3 ± 161 | 371 ± 191 | 342 ± 189 | − 34 ± 211 | 0.562 |
Glucose (mg/dl) AUC | 5739 ± 3359 | 4434 ± 2714 | − 1135 ± 2619 | 4118 ± 2132 | 4670 ± 2636 | 481 ± 3185 | 0.456 |
Insulin (mg/dl) AUC | 5456 ± 5074 | 5416 ± 3890 | 249 ± 4766 | 5765 ± 5342 | 6508 ± 5966 | 40 ± 6357 | 0.855 |
Free Fatty Acids (µmol/l) AUC | − 15.4 ± 28.7 | − 15.5 ± 13.4 | 2.0 ± 28.4 | − 19.3 ± 16.9 | − 22.3 ± 19.3 | − 3.1 ± 18.3 | 0.452 |